Seguridad de las pautas agrupadas de inmunoterapia subcutánea en el paciente polisensibilizado en Extremadura

Resumo

Allergen immunotherapy based on the administration of increasing doses of an allergen extract until an effective dose is repeated regularly. Allergen immunotherapy is indicated for a patient with allergic rhinoconjunctivitis and allergic bronchial asthma and in patients with Hymenoptera venom allergy. There is no single model used since the beginning of immunotherapy historical patterns start in twelve to twenty weeks through existing conventional patterns of five to eight weeks. In recent years, grouped patterns consist of rapid administration two to four weeks of high doses of allergen extract. Polysensitization from a clinical standpoint, poses a challenge diagnosis and treatment of our patients that are sensitized to several different pollens or panallergens responsible for cross-reactivity. In this scenario, the diagnosis is key to molecular components subsequent treatment with immunotherapy. The objective of this research is to analyze and describe local and systemic adverse reactions in the startup phase of cluster patterns in both adults and polysensitized to common pollens Extremadura, with clinical rhinoconjunctivitis and allergic bronchial asthma children.